TABLE 1.
Summary of pharmacological agents
| Pharmacological Agent | Abbreviation | Activity |
|---|---|---|
| α,β-Methylene-adenosine-5′-diphosphate | AMPCP | Inhibitor of ecto-5′-nucleotidase (CD73) |
| 2′,5′-Dideoxyadenosine | DDA | Inhibitor of adenylyl cyclase |
| 8-Bromo-3′,5′-cAMP | Br-cAMP | Membrane-permeable analogue of 3′,5′-cAMP that is not metabolized to adenosine |
| 1,3-Dipropyl-8-p-sulfophenylxanthine | DPSPX | At low concentrations is a nonselective adenosine receptor angatonist; at high concentrations inhibits ecto-phosphodiesterase |
| 8-Cyclopentyl-1,3-dipropylxanthine | DPCPX | Selective A1 adenosine receptor antagonist |
| Erythro-9-(2-hydroxy-3-nonyl)adenine | EHNA | Inhibitor of adenosine deaminase |
| Forskolin | FOR | Direct activator of adenylyl cyclase |
| 3-Isobutyl-1-methylxanthine | IBMX | Broad spectrum inhibitor of phosphodiesterases |
| 5-Iodotubercidin | ITUB | Inhibitor of adenosine kinase |
| (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine | KF17837 (KF) | Selective A2 adenosine receptor antagonist |
| 2′-Amino-3′-methoxyflavone | PD98059 | Blocks MAPK pathway by inhibiting MAPK kinase (MEK) |
| Platelet-derived growth factor-BB | PDGF-BB | Growth factor that activates the MAPK pathway |
| N-(2-methoxyphenyl)-N′-[2-(3-pyridinyl)-4-quinazolinyl]-urea | VUF5574 (VUF) | Selective A3 adenosine receptor antagonist |